Top-Line Efficacy Data Presented From Phase 2 Trial Of Alemtuzumab In Multiple Sclerosis

Genzyme Corporation (Nasdaq: GENZ) announced that top-line, three-year data from a completed Phase 2 clinical trial comparing alemtuzumab with Rebif(R) (interferon beta- 1a) for the treatment of multiple sclerosis were presented this weekend at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague. The results come from an analysis conducted after 36 months of treatment for 334 patients in the three-year trial. [click link for full article]

More: continued here

Filed under: Multiple Sclerosis on October 20th, 2007